# CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

> **NCT01191697** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 37 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** trastuzumab
- **DRUG:** oxaliplatin
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT01191697
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2021-12
- **Final completion:** 2024-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-11-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01191697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01191697, "CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01191697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*